SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-032692
Filing Date
2021-12-29
Accepted
2021-12-29 16:10:21
Documents
15
Period of Report
2021-12-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44678
2 ex5-1.htm EX-5.1 14059
3 ex10-1.htm EX-10.1 322739
4 ex5-1_001.jpg GRAPHIC 2911
  Complete submission text file 0001493152-21-032692.txt   636804

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE prph-20211227.xsd EX-101.SCH 2761
6 XBRL LABEL FILE prph-20211227_lab.xml EX-101.LAB 34476
7 XBRL PRESENTATION FILE prph-20211227_pre.xml EX-101.PRE 22603
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3647
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 211528966
SIC: 2834 Pharmaceutical Preparations